author-photo

Yuji Mishina

Novartis

16

Papers

1990

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

2019 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (14)
Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER

2019 Endocrinology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer

2018 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (64)
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (15)
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer

2017 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (23)
Abstract 330: Development of a highly selective B/CRAF kinase inhibitor that exhibits antitumor activities in RAS and BRAF mutant tumors with minimal paradoxical activation

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Inhibiting Tankyrases sensitizes KRAS mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling

2014 Cancer Research
Show All
- Source
- Cite
- Save
Citations (33)